DiaMedica Therapeutics (NASDAQ:DMAC) Issues Earnings Results
by Renee Jackson · The Cerbat GemDiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02), FiscalAI reports.
DiaMedica Therapeutics Trading Up 4.3%
DMAC stock traded up $0.27 on Wednesday, hitting $6.52. 184,771 shares of the company’s stock traded hands, compared to its average volume of 168,615. DiaMedica Therapeutics has a 1-year low of $3.47 and a 1-year high of $10.42. The stock has a market cap of $351.30 million, a price-to-earnings ratio of -9.31 and a beta of 0.99. The stock has a fifty day moving average of $6.92 and a 200-day moving average of $7.56.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.33.
Read Our Latest Stock Report on DMAC
Institutional Investors Weigh In On DiaMedica Therapeutics
A number of large investors have recently made changes to their positions in DMAC. Royal Bank of Canada raised its holdings in shares of DiaMedica Therapeutics by 46,879.1% during the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after acquiring an additional 154,701 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of DiaMedica Therapeutics by 76.7% during the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after acquiring an additional 52,854 shares during the period. Jane Street Group LLC raised its holdings in shares of DiaMedica Therapeutics by 138.5% during the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock valued at $382,000 after acquiring an additional 58,457 shares during the period. Geode Capital Management LLC raised its holdings in shares of DiaMedica Therapeutics by 99.6% during the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after acquiring an additional 314,407 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in shares of DiaMedica Therapeutics during the second quarter valued at approximately $49,000. Institutional investors and hedge funds own 10.12% of the company’s stock.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.
DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.